Validation, Commissioning & Design Featured Articles

1. A Site Bio-Decontamination Strategy: From Equipment Qualification To Process Ownership 11/2/2026

   Pharmaceutical manufacturers can evolve beyond an OEM-developed or qualified cycle to a proactive, well-defined and controlled bio-decontamination strategy that supports a defensible validation package.

2. Modern Site Operating Models For Complex Portfolios 10/31/2026

   When injectable and biologic volumes swing and disruption is barely tolerated, can a packaging plant organized by function keep pace? Splitting one site into focus factories suggests another model.

3. A Blueprint For GMP-Compliant Generative AI 10/21/2026

   Regulators have set terms for generative AI in GMP: bounded scope, traceable behavior, and human oversight where stakes are highest. Probabilistic models strain a framework built on reproducibility.

4. PDA TR33 And The Case For Rapid Methods In H₂O₂ Bio-Decontamination 10/14/2026

   The updated 2026 PDA Technical Report No. 33 offers a framework for qualifying alternative and rapid microbiological methods against traditional standards for regulatory compliance.

5. Why We Need Pharmaceutical Engineering Project Management As A Distinct Discipline 10/13/2026

   Applying general project management to a regulated setting as a variant of PMP or PRINCE2 is one of the most consistent, and most avoidable, causes of cost overrun and delayed start-up.

6. No Tricks, Just Treats: Inspection For Pharma And Nutraceuticals 10/5/2026

   Combining advanced inspection tools like NIR spectroscopy, X-ray, and checkweighing enables pharmaceutical manufacturers to detect contaminants, eliminate fill errors, and ensure compliance.

7. Audit-Ready EAM/CMMS Records 10/5/2026

   Maintenance and calibration records hold up under review only when executed work, changes, attachments, and exceptions travel together. Rehearsing retrieval shows whether an export carries the context another person needs.

8. ALCOA+ For Maintenance And Calibration Records 10/5/2026

   Calibration and maintenance records hold up only when the original result, any correction, and the resulting decision stay connected. The nine data-integrity principles show where that chain breaks.

9. The Orange Book's Blind Spot: Process Stability And Capability 10/5/2026

   The current system for assuring therapeutic equivalence contains structural blind spots. Companies must evolve rather than merely adding corrective actions.

10. Is Your Environmental Monitoring Protocol Designed For Real-World Effectiveness? 9/29/2026

    Integrating environmental monitoring performance qualification early in pharmaceutical facility design prevents regulatory issues, contamination risks, and costly manufacturing startup delays.